Wesley Buckingham

Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.

Joan-Anton Antón Puig-Butillé, Mercedes Marín-Aguilera, Pedro Jares, Sandra Cobo et autres

BACKGROUND: HER2DX is a validated genomic assay used to support treatment decisions in early-stage HER2-positive (HER2+) breast cancer. It provides three scores: relapse risk, likelihood of pathologic complete response (pCR), and ERBB2 mRNA expression. This study aimed to evaluate the association between …

us (code pays fourni par la source)

Supplementary Data 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

All the supplemental tables and figures

Figure 4 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

Associations between HER2DX ERBB2 score and pathologic variables. Distribution of HER2DX ERBB2 score groups (low, medium, and high; A); HER2DX ERBB2 score by tumor grade (B), HR status (C), HER2 IHC status (D), TLS status (E), and spatial immune distribution (F). All …

Figure 3 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

Associations between HER2DX risk score and pathologic variables. Distribution of HER2DX risk groups (low vs. high; A); HER2DX risk score by tumor grade (B), HR status (C), HER2 IHC status (D), TLS status (E), and spatial immune distribution (F). All scores are …

Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

Overview of patient and tumor characteristics. Patient distribution across the top 10 hospitals by enrollment (A), tumor grade (B), HR status (C), HER2 IHC status (D), Ki67 expression (E), stromal TIL percentage (F), TIL grouped as <20% vs. ≥20% (G), TLS status …

Data from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

AbstractPurpose: HER2DX is a validated genomic assay used to support treatment decisions in early-stage HER2-positive (HER2+) breast cancer. It provides three scores: relapse risk, likelihood of pathologic complete response (pCR), and ERBB2 mRNA expression. This study aimed to evaluate the association between …

Figure 2 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

Associations between HER2DX pCR score and standard pathologic features. Distribution of HER2DX pCR score groups (low, medium, and high; A); HER2DX pCR score by tumor grade (B), HR status (C), HER2 IHC status (D), TLS status (E), and spatial immune distribution (F). …

Figure 5 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

Correlations between HER2DX molecular modules and pathology features. Heatmap of Pearson correlation coefficients between HER2DX scores/modules (pCR score, risk score, ERBB2 score, IGG, proliferation, and luminal) and pathologic features (TIL%, Ki67, HR status, TLS, HER2 IHC, tumor grade, and spatial pattern; A); …

Table 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo et autres

Associations between HER2DX scores and histopathologic variables.

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín‐Aguilera, Sandra Cobo et autres

PURPOSE: HER2DX is a validated genomic assay used to support treatment decisions in early-stage HER2-positive (HER2+) breast cancer. It provides three scores: relapse risk, likelihood of pathologic complete response (pCR), and ERBB2 mRNA expression. This study aimed to evaluate the association between …

us, es, ie (code pays fourni par la source)

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

Kazuki Nozawa, Laia Paré, Naomi Gondo, Fumikata Hara et autres

Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy …

us (code pays fourni par la source)

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

Kazuki Nozawa, Masataka Sawaki, Yukari Uemura, Michiko Tsuneizumi et autres

Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy …

jp, es, us (code pays fourni par la source)